Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients
Prevalence of the Mutational Status of KRAS in mCRC in Argentine Patients
調査の概要
状態
条件
詳細な説明
This is an observational, prospective, non-interventional, single arm, non-comparative, open label, multi-centric, multi-stage study to record the prevalence of KRAS mutations in the Argentine mCRC population. The study is planned to be conducted in 150 centres (50 in each of 3 stages of four months each, enrolling 500 subjects in each stage). Total of subjects: 1500. Demographic information, complete medical history and tumour history related data will be captured in the first visit and if any information is missing, then only another visit will be scheduled. Data captured will be analysed and presented using statistical tools.
OBJECTIVES:
Primary objective:
- To record the prevalence of KRAS mutations in the Argentine mCRC population.
Secondary objective:
- To record and evaluate certain subject and tumour characteristics for association with KRAS mutational status (country, gender, age, performance status, body mass index (BMI), ethnic origin, personal and family history of malignancy, personal and family history of familial polyposis coli, smoking status, exercise, diet, tumour characteristics/location, site of origin of the tissue sample sent for KRAS testing, first line therapy chosen).
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Vicente Lopez、アルゼンチン
- Htal Vicente Lopez
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Subjects who have signed written informed consent before any study-related procedure
- Subjects with histologically confirmed adenocarcinoma of the colon/ rectum, T1-4 N0-2 M1 or rT1-4 N0-2 M1
- Subjects with age above 21 years
- Subjects willing to provide information required by protocol
- No previous systemic treatment for mCRC
Exclusion Criteria:
- Subjects with known pregnancy
- Subjects with previous systemic therapy for mCRC
- Subjects with active infection or any other serious condition which, in the investigator´s mind, may render the subject ineligible for the study
- Subjects with medical or psychological condition, which, in the opinion of the investigator, would not permit the subject to sign meaningful informed consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Mutational status of KRAS: study of codons 12 and 13 in exon 1 of KRAS gene
時間枠:Initial visit (Day 1) and subsequent visit till the end of the study
|
Initial visit (Day 1) and subsequent visit till the end of the study
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Subject and tumour characteristics and their association with KRAS mutational status
時間枠:Initial visit (Day 1) and subsequent visit till the end of the study
|
Initial visit (Day 1) and subsequent visit till the end of the study
|
協力者と研究者
捜査官
- スタディディレクター:Medical Director、Merck Quimica Argentina S.A.I.C
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。